STAAR SURGICAL COMPANY
| Revenue | $187.1M |
|---|---|
| Operating income | $18.1M |
| Net income | $13.3M |
| Free cash flow | $-2.9M |
| Operating margin | 9.7% |
| Net margin | 7.1% |
| Return on equity | 3.6% |
| Period | 2026 |
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
STAAR delivered a strong Q2:
revenue rose 111% to $93.5M, China reached $52.3M (+100%+ YoY, +10% sequentially), gross margin was 74.5%, and adjusted EBITDA improved to $20.0M from a $14.8M loss. The bull case is rapid EVO Plus share capture in China and continued displacement of laser vision correction, but the investment is not de-risked: China is the dominant growth engine, Q3 is expected to be seasonally lower than Q2, supply constraints are limiting sales, and management would not quantify the China growth algorithm or answer analysts’ ASP and volume math directly.
Near term
Q3 revenue will be seasonally below Q2 in China, although management expects year-over-year growth after adjusting the Q3 2025 comparison for the $25.9M one-time order; Q4 is also expected to grow but will be seasonally softer.
EVO Plus was approximately one-third of China units exiting Q2 and carries a meaningful premium, but management expects supply to become sufficient only around the end of Q3. Backorders, including U.S. made-to-order lenses, remain a near-term execution constraint.
Gross margin should benefit from lower ERP consulting costs beginning in Q4 and reduced Switzerland ramp costs, but China tariffs on U.S.-manufactured products remain a headwind until the transition to 100% Swiss manufacturing by year-end 2026.
The U.S. remained around $6M for a second consecutive quarter rather than continuing its prior sequential growth pattern; management attributed the softness partly to a declining overall laser/refractive market and product availability.
Longer term
China share gains are the central thesis, but analysts explicitly questioned whether EVO Plus pricing is masking declining underlying units. Management cited share capture and a V4c halo effect but provided no quantified unit-growth or market-share data.
Competitive durability remains unresolved. Management welcomed domestic Chinese competition and pointed to Collamer’s safety history and surgeon trust, but did not quantify switching, pricing, clinical differentiation, or the likely impact of competing acrylic lenses.
The U.S. opportunity is substantial but still early and economically complicated: surgeons must build profitable in-office or ASC models, and the company acknowledged it is not capturing all of the laser market’s declines.
The proposed platform beyond EVO is strategically promising but unproven. A CTO search is ongoing and first-in-human testing for next-generation products may begin as early as 2027; there is not yet a defined product, market, investment level, or commercialization timeline.
Cash generation and the debt-free balance sheet provide flexibility, with $181.5M of cash and investments at quarter-end, but future returns depend on converting that financial capacity into reliable supply expansion and successful R&D rather than simply higher spending.
Red flags
Supply has already lagged accelerating demand, creating backorders and potentially capping reported growth even while demand appears strong. Management’s claim that capacity should be adequate by the end of Q3 is not yet demonstrated.
China represented approximately 56% of Q2 revenue, creating substantial geographic and concentration risk. China’s refractive market was described as flat to mid-single-digit growth, while the company declined to provide a specific normalized China growth range.
The analyst challenge around China pricing and volume was not fully resolved: with roughly one-third of exit units being EVO Plus and a substantial premium, the implied revenue growth may overstate underlying unit momentum.
Gross-margin expansion was modest at 50 basis points despite the significant revenue increase, and tariffs will continue to pressure margins through 2026. The company also left open the possibility of spending above its $225M target for targeted investments.
Management characterized ERP revenue disruption as negligible, but acknowledged possible lost sales in made-to-order lenses and continued system stabilization work, leaving some operational execution risk.
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.